Skip to content

Catalysts Convergence Squeeze SignalsNEW Cash Runway Insiders M&A Research

Sign In Start 14-Day Free Trial

Home›Companies›American Resources Corp (AREC)

American Resources Corp

AREC

Held by 1 specialist biotech fund

1 fund opened new positions. Short interest: 9.2% of float.

Share

Score Holdings Short Interest Catalysts Insiders Research

Signal Score

1.5/10

1 fund opened new positions

B

BiotechEdge

Catalysts Conferences Companies Convergence Fund Insiders Signals Squeeze Cash Runway Research Weekly Briefs 13F Changes Glossary PricingSign In Start 14-Day Free Trial

Data sourced from SEC EDGAR and ClinicalTrials.gov. Not investment advice.

●●

No recent insider activity●●

No upcoming catalysts●●

Held by 1 specialist fund●●

See how each signal contributes— fund overlap, insider activity, catalyst timing, short interest (free trial)

Fund Holdings

Driehaus CapitalNew

AI Signal

Signal Note – AREC / Driehaus Capital (Caldwell)

Driehaus Capital's Michael Caldwell, running a growth-oriented book with meaningful biotech exposure, initiated a new ~2.4M share position in American Resources Corp (AREC) worth ~$5.8M — notable given AREC is primarily a critical materials/rare earth company, not a traditional biotech name, suggesting Caldwell may be playing the industrial/defense supply chain angle rather than a drug catalyst. The position size is meaningful for a name at this market cap, but investors should note AREC's historically thin cash position and recurring capital needs, flagging real dilution risk if operational cash burn continues without revenue scaling.

Unlock full AI analysis — 14-day free trial

Short Interest

SI rising 2 periods (+8.5%)

Short Shares

9.62M

Change

+7.4%

Days to Cover

2.7

% of Float

9.2%

Settlement

Jun 15, 2026

Short interest over 7 periods

Catalysts

No catalysts tracked.

Be first to know when this name moves

Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.

Position Details

Driehaus CapitalNEW POSITIONMay 15, 2026

Start free trialfor share counts, dollar values & AI analysis

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Also Held by These Funds

ANDG1 fund AAPL1 fund APLD1 fund CMI1 fund EQIX1 fund CUBB1 fund ESE1 fund MOD1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts:

AREC: Held by 1 Biotech Hedge Fund (2026) | BiotechEdge